178 related articles for article (PubMed ID: 25076845)
1. Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance.
Lee SH; Yoo C; Im S; Jung JH; Choi HJ; Yoo J
Int J Med Sci; 2014; 11(10):994-1000. PubMed ID: 25076845
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Marquard L; Poulsen CB; Gjerdrum LM; de Nully Brown P; Christensen IJ; Jensen PB; Sehested M; Johansen P; Ralfkiaer E
Histopathology; 2009 May; 54(6):688-98. PubMed ID: 19438744
[TBL] [Abstract][Full Text] [Related]
3. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract][Full Text] [Related]
4. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
Park E; Lee C; Park J; Liu J; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Leuk Lymphoma; 2023 Jan; 64(1):205-216. PubMed ID: 36331521
[TBL] [Abstract][Full Text] [Related]
5. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.
Gupta M; Han JJ; Stenson M; Wellik L; Witzig TE
Leukemia; 2012 Jun; 26(6):1356-64. PubMed ID: 22116549
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
Müller BM; Jana L; Kasajima A; Lehmann A; Prinzler J; Budczies J; Winzer KJ; Dietel M; Weichert W; Denkert C
BMC Cancer; 2013 Apr; 13():215. PubMed ID: 23627572
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract][Full Text] [Related]
8. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
9. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
10. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
Weichert W; Röske A; Gekeler V; Beckers T; Ebert MP; Pross M; Dietel M; Denkert C; Röcken C
Lancet Oncol; 2008 Feb; 9(2):139-48. PubMed ID: 18207460
[TBL] [Abstract][Full Text] [Related]
11. Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.
Min SK; Koh YH; Park Y; Kim HJ; Seo J; Park HR; Cho SJ; Kim IS
Korean J Pathol; 2012 Apr; 46(2):142-50. PubMed ID: 23109994
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
13. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
Weichert W; Röske A; Gekeler V; Beckers T; Stephan C; Jung K; Fritzsche FR; Niesporek S; Denkert C; Dietel M; Kristiansen G
Br J Cancer; 2008 Feb; 98(3):604-10. PubMed ID: 18212746
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL).
Markovic O; Marisavljevic D; Cemerikic-Martinovic V; Martinovic T; Filipovic B; Stanisavljevic D; Zivković R; Hajder J; Stanisavljevic N; Mihaljevic B
Med Oncol; 2012 Dec; 29(5):3515-21. PubMed ID: 22528517
[TBL] [Abstract][Full Text] [Related]
18. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.
Ohshima K; Kawasaki C; Muta H; Muta K; Deyev V; Haraoka S; Suzumiya J; Podack ER; Kikuchi M
Histopathology; 2001 Aug; 39(2):156-62. PubMed ID: 11493332
[TBL] [Abstract][Full Text] [Related]
19. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.
Johnson DP; Spitz GS; Tharkar S; Quayle SN; Shearstone JR; Jones S; McDowell ME; Wellman H; Tyler JK; Cairns BR; Chandrasekharan MB; Bhaskara S
Oncotarget; 2015 Mar; 6(7):4863-87. PubMed ID: 25605023
[TBL] [Abstract][Full Text] [Related]
20. HDAC1 and HDAC2 regulate anti-inflammatory effects of anesthetic isoflurane in human monocytes.
Guo X; Deng J; Zheng B; Liu H; Zhang Y; Ying Y; Jia J; Ruan X
Immunol Cell Biol; 2020 Apr; 98(4):318-331. PubMed ID: 31950542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]